- Home
- GNS vs BCTX Comparison
GNS vs BCTX Comparison
Compare GNS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- BCTX
- Stock Information
- Founded
- GNS 2002
- BCTX 2014
- Country
- GNS Singapore
- BCTX Canada
- Employees
- GNS N/A
- BCTX N/A
- Industry
- GNS Other Consumer Services
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- BCTX Health Care
- Exchange
- GNS Nasdaq
- BCTX Nasdaq
- Market Cap
- GNS 17.8M
- BCTX 16.1M
- IPO Year
- GNS 2022
- BCTX N/A
- Fundamental
- Price
- GNS $0.36
- BCTX $3.00
- Analyst Decision
- GNS
- BCTX Strong Buy
- Analyst Count
- GNS 0
- BCTX 1
- Target Price
- GNS N/A
- BCTX $32.00
- AVG Volume (30 Days)
- GNS 2.5M
- BCTX 3.7M
- Earning Date
- GNS 04-30-2025
- BCTX 06-13-2025
- Dividend Yield
- GNS N/A
- BCTX N/A
- EPS Growth
- GNS N/A
- BCTX N/A
- EPS
- GNS N/A
- BCTX N/A
- Revenue
- GNS $7,912,718.00
- BCTX N/A
- Revenue This Year
- GNS $233.65
- BCTX N/A
- Revenue Next Year
- GNS $570.20
- BCTX N/A
- P/E Ratio
- GNS N/A
- BCTX N/A
- Revenue Growth
- GNS N/A
- BCTX N/A
- 52 Week Low
- GNS $0.21
- BCTX $0.35
- 52 Week High
- GNS $5.69
- BCTX $9.82
- Technical
- Relative Strength Index (RSI)
- GNS 53.04
- BCTX 35.60
- Support Level
- GNS $0.30
- BCTX $3.09
- Resistance Level
- GNS $0.45
- BCTX $9.82
- Average True Range (ATR)
- GNS 0.05
- BCTX 0.35
- MACD
- GNS 0.00
- BCTX -0.18
- Stochastic Oscillator
- GNS 41.45
- BCTX 0.83
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.